checkAd
    Arrowhead Pharmaceuticals Aktie
    22,950
     
    USD
    +0,75 %
    +0,170 USD
    Letzter Kurs 02:00:00 Nasdaq
    22,960
     
    USD
    1.900 STK
    Geldkurs 31.05.24
    22,990
     
    USD
    2.200 STK
    Briefkurs 31.05.24
    ISIN: US04280A1007 · WKN: A2AGYB · SYM: ARWR · USA

    Neueste Nachrichten

    Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
    31.05.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
    29.05.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
    28.05.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
    20.05.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
    09.05.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
    02.05.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
    29.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
    26.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
    24.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
    24.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
    07.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals
    Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    01.04.24 · Business Wire (engl.) · Arrowhead Pharmaceuticals